Terumo Medical Expands Manufacturing in Puerto Rico

Terumo Medical Corporation (TMC) is investing $30 mn to expand its manufacturing capabilities in Puerto Rico and meet the increasing global demand for its Angio-Seal vascular closure device. With completion targeted for summer 2025, the new 64,000-square-foot facility will complement existing operations at the site and enhance production capacity and efficiency. The expansion not only underscores Terumo's commitment to global healthcare improvement but promises continued job security for its 340 local employees.

Terumo Medical Corporation (TMC) broke ground recently on a new manufacturing facility at its Caguas, Puerto Rico site. This expansion is another investment by Terumo as global demand for the company’s Angio-Seal® Vascular Closure Device (VCD), manufactured in Puerto Rico, continues to increase. Angio-Seal is one of the leading vascular closure devices on the global market, used on millions of patients globally. It provides active closure for rapid and reliable hemostasis in patients who have undergone angiographic or interventional procedures. It also has been proven to accelerate patient mobility and enable same-day discharge, which means patients have the potential to be home for recovery soon after their procedures.

The new, 64,000-square-foot expansion will be built adjacent to the existing site and is scheduled to be completed by summer 2025. The existing, 22,000-square-foot building will also be renovated to support related production administration requirements.

“Terumo is a global leader in entry site management, and our Angio-Seal Vascular Closure Device is an important, highly regarded product within this category,” said Jim Rushworth, President & CEO, Terumo Medical Corporation. “Expanding production capacity in Puerto Rico will enable us to meet growing demand. It is yet another strategic investment by Terumo to set us up for future growth, maintain our global success, and better support our healthcare-provider customers and, importantly, their patients.”

“This new building deepens our commitment to our customers, to the island of Puerto Rico, and to our 340 dedicated Terumo associates who work each day to provide for our customers,” said Rafael Benitez, Senior Director, TPR Site Leader. “We are very proud to be part of this community, where we have operated as a Terumo subsidiary since 2017, and look forward to a long and lasting partnership.”

For more, please find the original story source here.

Previous
Previous

Terumo Launches Study for Resorbable Microsphere Efficacy in Liver Cancer Treatment

Next
Next

What’s Next in mRNA After COVID-19?